Skip to main content
Tags: martin shkreli | office | emails | drug | price

Martin Shkreli, Pharma CEO, Plotted to Raise Drug Prices, Emails Show

Martin Shkreli, Pharma CEO, Plotted to Raise Drug Prices, Emails Show
Martin Shkreli (C), a former hedge fund manager and CEO of Retrophin, leaves the federal court after getting bail in New York on December 17, 2015. (Jewel Samad/AFP/Getty Images)

By    |   Wednesday, 03 February 2016 03:53 PM EST

Martin Shkreli, former CEO of Turing Pharmaceuticals and media poster child for drug price hikes, had thousands of his emails and other correspondence released by congressional Democrats on Tuesday.

"We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us," Shkreli wrote in one email, referring to the cancer and AIDS drug Daraprim, The Associated Press reported.

"$1bn here we come," Shkreli reportedly said in another message, according to CNN Money.

Rep. Elijah Cummings, D-Maryland, a member of the House Committee on Oversight and Government Reform, said after releasing Shkreli's communiques "that many drug companies are lining their pockets at the expense of some of the most vulnerable families in our nation."

Shkreli, 32, became notorious in the media last year for the Daraprim price hike, as well as for purchasing the world's only copy of a hip-hop album by the Wu-Tang Clan rap group.

He was denounced by both Hillary Clinton and Bernie Sanders on their respective campaign trails.

In addition to the investigation by the House committee, Shkreli is also facing "civil and criminal securities fraud charges" related to his hedge fund activities, The Wall Street Journal reported

He appeared in a Brooklyn courthouse on Wednesday to face those charges.

According to the AP, "On Wednesday, a prosecutor told the judge that the value of a brokerage account used to secure Shkeli's release on $5 million bond — mostly invested in a biotech business once operated by Shkeli — had declined, and that more collateral may be needed if it goes down any further. Brafman said it wasn't surprising the account took a hit."

The House committee is scheduled to hear testimony from Turing's chief commercial officer, Nancy Retzlaff, on Thursday.

© 2025 Newsmax. All rights reserved.


TheWire
Martin Shkreli, former CEO of Turing Pharmaceuticals and media poster child for drug price hikes, had thousands of his emails and other correspondence released by congressional Democrats on Tuesday.
martin shkreli, office, emails, drug, price
294
2016-53-03
Wednesday, 03 February 2016 03:53 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the Newsmax App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved